Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis

British Journal of Ophthalmology

Volumn 95, Issue 2, 2011, Pages 209-213

  Goebel, J C ^a   Roesel, M ^a   Heinz, C ^a   Michels, H ^b   Ganser, G ^c   Heiligenhaus, Arnd ^a  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b German Centre for Pediatric and Adolescent Rheumatology   (Germany)

^c St Josef Stift ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MALE; MONOTHERAPY; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STOMACH PAIN; UVEITIS;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS;

EID: 79251468763     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.173542     Document Type: Article

References (25)

1. Andersson Gare B. Juvenile arthritis - who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999;17:367-74.
2. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29:1520-30.
3. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-2.
4. Carvounis PE, Herman DC, Cha S, et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006;244:281-90.
5. Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-19.
6. Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002;86:51-6.
7. Paroli MP, Speranza S, Marino M, et al. Prognosis of juvenile rheumatoid arthritis-associated uveitis. Eur J Ophthalmol 2003;13:616-21.
8. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986;13:118-23.
9. Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 1997;24:2444-50.
10. Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992;32:241-52.
11. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
12. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
13. Hinzpeter EN, Naumann G, Bartelheimer HK. Ocular histopathology in Stillś disease. Ophthalmic Res 1971;2:16-24.
14. Sabates R, Smith T, Apple D. Ocular histopathology in juvenile rheumatoid arthritis. Ann Ophthalmol 1979;11:733-7.
15. Merriam JC, Chylack LT Jr, Albert DM. Early onset pauciarticular juvenile rheumatoid arthritis: a histopathologic study. Arch Ophthalmol 1983;101:1085-92.
16. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond) 2009;23:1192-8.
17. Parikh JG, Tawansy KA, Rao NA. Immunhistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 2008;115:1833-6.
18. Elion GB, Hitchings JH. Azathioprine. In: Sartorelli AC, Johns DG, eds. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1975. 38:404-25.
19. McKendry RJR. Purine antagonists. In: Dixon J, Furst DE, eds. Second line agents in the treatment of rheumatic diseases. New York: Marcell Dekker, 1991.
20. Bacon PA, Salmon M. Modes of action of second line agents. Scand J Rheumatol Suppl 1987;64:17-24.
21. Hildner K, Märker-Hermann E, Schlaak JF, et al. Azathioprine, mycophenolate mofetil and methotrexate specifically modulate cytokine production by T cells. Ann NY Acad Sci 1998;859:204-7.
22. El-Yazigi A, Wahab FA. Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. J Clin Pharmacol 1993;33:522-6.
23. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32:362-5.
24. Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007;17:743-8.
25. Fuentes D, Torrente F, Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:913-21. (Pubitemid 36459604)